Colleen Kusy
Stock Analyst at Baird
(1.65)
# 3,424
Out of 5,152 analysts
51
Total ratings
35.56%
Success rate
-0.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Neutral | $858 → $867 | $728.11 | +19.08% | 2 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $100.13 | +57.79% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $37.46 | -9.24% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $20.15 | +158.06% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $10.33 | +132.33% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $7.39 | +21.79% | 1 | Aug 15, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $29.29 | +77.53% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $2.92 | +105.48% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $27.74 | +47.80% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.76 | +240.91% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $65 | $40.59 | +60.14% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $13.85 | +80.51% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $8.82 | +2,280.95% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $4.58 | +642.36% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.81 | +5,936.75% | 1 | Nov 2, 2021 |
argenx SE
Feb 27, 2026
Maintains: Neutral
Price Target: $858 → $867
Current: $728.11
Upside: +19.08%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $100.13
Upside: +57.79%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $37.46
Upside: -9.24%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $20.15
Upside: +158.06%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $10.33
Upside: +132.33%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $7.39
Upside: +21.79%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $29.29
Upside: +77.53%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $2.92
Upside: +105.48%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $27.74
Upside: +47.80%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.76
Upside: +240.91%
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $40.59
Upside: +60.14%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $13.85
Upside: +80.51%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $8.82
Upside: +2,280.95%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $4.58
Upside: +642.36%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.81
Upside: +5,936.75%